NCT06490055Completed
Predicting the Efficacy in Advanced Gastric Cancer.
Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer.
Source: ClinicalTrials.gov · Last updated 18 Jul 2025
Brief summary (registry, in English)
With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 162 (actual)
- First submitted
- 21 Jun 2024
- Start date
- 1 Oct 2018
- Primary completion date
- 18 Feb 2025
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06490055
What you commit to
- Study type: Observational
- Participants enrolled: 162
- From 1 Oct 2018 to the primary completion date, 18 Feb 2025
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency.
- Patients with a history of serious allergic reactions or serious drug allergy.
- Patients with a clinically relevant mental disorder that prohibits response to questionnaires.
Other
- Patients with a life expectancy of shorter than 3 months
- Patients for whom the attending physician considered that enrollment in the study is inappropriate.
Who the study is looking for
- unresectable or recurrent GC histologically confirmed to be primary adenocarcinoma of the stomach.
- age over 20 years.
- Eastern Cooperative Oncology Group performance status score of 0-2.
- written informed consent following full study information is provided to the patient.
- progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced GC.
- presence of evaluable lesions as confirmed using a computed tomography (CT) or magnetic resonance imaging.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kawasaki Medical University Coordinator of this site? Confirm its status | Kurashiki | Japan | Unknown status |
| Department of Molecular Diagnostics and Experimental Therapeutics Coordinator of this site? Confirm its status | Monrovia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.